Prethivan

Higher Specialty Trainee in Diabetes & Endocrinology

[Hypertension @HyperAHA]

REVIEW: Subtyping of Primary Aldosteronism in Partial Adrenal Vein Sampling: The Relative Aldosterone Secretion Index

https://t.co/KyRPyQYOpF

[Prethivan @prethivan]

PA exist in a continuum.Prevalence of PA among pts with low renin HTN is significantly higher than other causes.MRA is very helpful in reducing complication rate among low renin HTN pts.These pts will very likely have PA in the future/it's just that we've not diagnosed them yet.

[Anand Vaidya @AnandVaidya17]

Low-renin hypertension in incidental adrenal adenomas and response to aldosterone-targeted therapy: a prospective study @renebaudrand @ThomasUslar

https://t.co/wRsDEThszS

[Anand Vaidya @AnandVaidya17]

Primary Aldosteronism

https://t.co/2UXteCsv8n

[Anand Vaidya @AnandVaidya17]

Low-renin hypertension in incidental adrenal adenomas and response to aldosterone-targeted therapy: a prospective study @renebaudrand @ThomasUslar

https://t.co/wRsDEThszS

[Prethivan @prethivan]

Had an incredible week at #ENDO2026. Sharing our PPGL research, learning from colleagues around the world, and enjoying everything Chicago had to offer 🌇✨

[Euro J Endocrinology @EJEndo]

Evaluating the impact of adrenalectomy and mineralocorticoid receptor antagonists for primary aldosteronism on left ventricular remodeling: a systematic review and meta-analysis by Yu-Ching Chang @ChengHsuanTsai et al 👉 https://t.co/jl1dbmsVKY

[Hypertension @HyperAHA]

REVIEW: Emerging Medical Therapies for Primary Aldosteronism

https://t.co/AWsAiEyysN

[Hypertension @HyperAHA]

REVIEWER: Aldosterone and the Mineralocorticoid Receptor in Atrial Fibrillation

https://t.co/Ma1PMWd9jg

[Prethivan @prethivan]

Existing models for PPGL use metadrenalines as binary-elevated or not for prognostication. But we explored the role of quantitative metadrenaline burden. Excited to receive @TheEndoSociety Outstanding Abstract Award! Will be presenting at ENDO 2026 June 13, 1:45 PM :)
#ENDO2026

[Endocrine Society @TheEndoSociety]

Outstanding Abstract Award Winners | We are pleased to announce our cohort of outstanding abstract awardees for ENDO 2026. View this year's winners: https://t.co/KkFywPJ7Ia #ENDO2026 #endocrinology

[Hypertension @HyperAHA]

COMMENTARY: Beyond Spironolactone: Does Next Generation of Aldosterone Blockade Add Value?

https://t.co/ahHEg158rP

[Ahmed Bennis MD 🫀 @drbennisahmed]

🫀 Don’t stop spironolactone just because eGFR dips.
TOPCAT Americas analysis (1,648 HFpEF patients):
• 26% had early acute eGFR decrease ≥15% — and it was adversely prognostic
• Early eGFR dip → HR 3.53 for sustained renal decline/ESKD/renal death
• Yet spironolactone consistently reduced CV death, HF hospitalization & aborted cardiac arrest vs. placebo (P-interaction = 0.64)
The CV benefit persisted regardless of early eGFR change.
An acute eGFR dip after MRA initiation should not automatically trigger discontinuation.
#HFpEF #Cardiology #HeartFailure #MedTwitter

[Maribel del Olmo @drdelolmo_mbel]

📢 New multicenter collaboration
🧬 Metastatic paragangliomas & pheochromocytomas
📊 Response & survival patterns
🤝 Two Spanish centers
Now published in Journal of Neuroendocrinology (JNE) 📖
Science moves forward together 💙 @HospitalLaFe @VHIO @vallhebron @PheoPara @APheipas

[Grupo GETNE @GrupoGetne]

🧬 Advanced ACC: new prognostic model (ENSAT)

📊 Multicenter cohort (n=418)

🔑 Key factors
• Tumor burden
• Cortisol excess
• ECOG-PS
• NLR ≥5

📈 ENSAT Risk Score
➡️ Score >2 = poor prognosis
➡️ Predicts OS, TTP & treatment response

🔗 https://t.co/TRhFD4XbDW

[Birmingham Adrenal Team @Bham_AT]

🚨📅 SAVE THE DATE! Our @unibirmingham @unibirm_CMH Birmingham Adrenal Tumour Masterclass will be back on 12/09/2026.
Registrations opening soon!
ℹ️ Topic: secondary #hypertension & primary aldosteronism #primaryaldo #adrenal
🔗https://t.co/u8ZKxKjey7

[Prethivan @prethivan]

Grateful to be selected for the Early Career Forum Award by the @TheEndoSociety. Looking forward to the upcoming meeting ! :)

#ENDO2026

[Endocrine Society @TheEndoSociety]

Congratulations to our Early Career Forum program winners. Our awardees will attend ENDO 2026 and participate in a unique workshop to connect them with experts in the field. View our awardees: https://t.co/BHcQqeAjAG #ENDO2026 #endocrinology

[Prethivan @prethivan]

Our study has been accepted as a rapid-fire presentation at ENDO 2026 Conference!

“Quantitative Metadrenaline Burden and Tumour Characteristics Predict Prognosis in PPGL: A 12-Year Single Centre Cohort Study.”

Looking forward to presenting our findings :)

#ENDO2026

[Prethivan @prethivan]

@AddisonsUK @Soc_Endo Thank you ! It is my pleasure working with the ADHSG panel :)

[Prethivan @prethivan]

Honored to share our work in the Adrenal Network session at #SfEBES2026, on the novel HISTAR score-integrating CYP11B2 immunohistochemistry with clinical predictors to enhance cure prediction post adrenalectomy in primary aldosteronism. Grateful for the engaging discussion !

[Prethivan @prethivan]

Pleased to share our newly published case series on RFX6-MODY, highlighting clinical considerations in pregnancy and the first documented use of tirzepatide post pregnancy in this rare MODY subtype. Thanks to all my co-authors!

[EDMCaseReports @EDMCaseReports]

RFX6-MODY is a MODY subtype, with limited management guidance, particularly in pregnancy.

A new case series by Prethivan Pillai Gopalakrishnan et al. offers insight into clinical features & management of two patients diagnosed during pregnancy.

🔓https://t.co/8mPphaRFkJ

#MODY

[Prethivan @prethivan]

Delighted to win the Best Oral Presentation Award at the recent Northwest Endocrine Society Meeting! Was a pleasure to share our study on the diagnostic value of saline infusion test in predicting lateralisation in primary aldosteronism among intermediate probability patients